Today
Hot Stocks
Show Hide Related Items >> <<
01/14/21 Oragenics issues letter to stockholders on Terra CoV-2 01/12/21 Moderna appoints Jose Vega as chief safety officer 01/12/21 Uber, Moderna to collaborate on 'uptake of COVID-19 vaccines' 01/12/21 Moderna announces Swissmedic authorization for COVID-19 vaccine in Switzerland 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/06/21 Piper Sandler Moderna price target raised to $170 after EU vaccine approval at Piper Sandler 01/04/21 Piper Sandler Moderna shares warrant 'fresh look' after 41% pullback, says Piper Sandler 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) 10/28/20 Notable companies reporting before tomorrow's open 10/28/20 Notable companies reporting before tomorrow's open 08/05/20 Moderna reports Q2 EPS (31c), consensus (35c)
Options
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: GameStop (GME) 54.15% +23.38, 500.com (WBAI) 236.19% +14.67, BioNTech SE (BNTX) 28.64% +10.50, (GNOG) 10.42% +7.63, Platinum Group (PLG) 40.92% +6.84, Cel Sci (CVM) 71.20% +6.17, Vuzix (VUZI) 48.96% +4.89, Ideanomics (IDEX) 24.77% +3.71, B Riley Principal Merger Corp II (EOSE) 33.59% +3.68, and ContextLogic (WISH) 14.48% +3.51.
Show Hide Related Items >> <<
01/12/21 500.com falls -6.2% 01/11/21 500.com rises 10.6% 01/06/21 500.com rises 18.2% 01/05/21 500.com falls -14.5% 01/11/21 Vuzix confirms joint manufacturing and supply agreement with Jade Bird 12/29/20 Vuzix receives follow-on M400 Smart Glasses order 12/22/20 Vuzix enters supply agreement with large general merchandise retailer in U.S. 12/02/20 Vuzix announces follow-on order from Pixee Medical 01/15/21 Ideanomics announces MEG December, Q4 sales activity 01/05/21 Ideanomics to acquire Utah-based wireless charging provider WAVE 12/28/20 Ideanomics' MEG enters pruchase agreement for 2,000 units of BYD DI 12/28/20 Cryptocurrency mining related names rise after Bitcoin spike this weekend 01/17/21 Fly Intel: Top five weekend stock stories 01/15/21 December video game spending grew 25% y/y to $7.7B, says NPD 01/14/21 GameStop director sells 810K shares of common stock 01/14/21 GameStop rises 18.1% EOSE Eos Energy Enterprises 01/13/21 Eos Energy Enterprises logged $16M of booked orders as of Dec. 31 01/04/21 Eos Energy Enterprises secures $20M order for long duration storage 12/22/20 Eos Energy Enterprises secures order from Charge Bliss 12/09/20 Eos Energy Enterprises enters agreements with four companies valued at $2.5M 12/07/20 CEL-SCI announces update on Phase 3 cancer trial results 12/01/20 CEL-SCI's LEAPS peptides demonstrate clear survival benefit in COVID treatment 09/18/20 CEL-SCI awarded European patent for LEAPS vaccine in treatment of RA 09/15/20 CEL-SCI issue letter to shareholders regarding Multikine development program 01/12/21 Canada orders 20M more doses of Pfizer, BioNTech Covid vaccine 01/08/21 Pfizer, BioNTech COVID vaccine elicits antibodies that neutralize mutation 01/07/21 BioNTech reports publication of preclinical data on novel mRNA vaccine approach 01/04/21 FDA continues to recommend authorized COVID vaccine dosing schedule 01/13/21 Standpoint Research GameStop downgraded to Hold from Buy at Standpoint Research 01/11/21 Benchmark Benchmark 'not surprised' by GameStop board change after 'disappointing' holiday 12/09/20 Benchmark GameStop price target lowered to $5 from $6 at Benchmark 12/04/20 Wedbush GameStop price target raised to $16 from $8 at Wedbush 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 12/29/20 Citi Arcturus selloff brings 'very good' buying opportunity, says Citi 12/22/20 Roth Capital Translate Bio price target raised to $37 from $30 at Roth Capital 12/15/20 Jefferies Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play' GNOG Golden Nugget Online 01/13/21 Benchmark Golden Nugget Online initiated with a Buy at Benchmark 05/14/20 H.C. Wainwright CEL-SCI price target raised to $23 from $18 at H.C. Wainwright 08:10 Today Maxim Vuzix price target raised to $13 from $6.50 at Maxim 09/04/20 Craig-Hallum Vuzix price target raised to $8 from $6 at Craig-Hallum 05/11/20 Alliance Global Partners Vuzix downgraded to Neutral from Buy at Alliance Global Partners EOSE Eos Energy Enterprises 01/15/21 B. Riley Securities Eos Energy Enterprises price target raised to $35 from $23 at B. Riley 12/10/20 B. Riley Securities Eos Energy Enterprises price target raised to $22 from $17 at B. Riley Securities 11/20/20 Fly Intel: Top five analyst initiations 11/20/20 B. Riley Securities Eos Energy Enterprises initiated with a Buy at B. Riley Securities 01/11/21 JPMorgan ContextLogic initiated with an Overweight at JPMorgan 01/11/21 UBS ContextLogic initiated with a Buy at UBS 01/11/21 Credit Suisse ContextLogic initiated with an Outperform at Credit Suisse 01/11/21 Loop Capital ContextLogic initiated with a Hold at Loop Capital 01/15/21 Vuzix reports preliminary Q4 revenue $4M, consensus $3.52M 11/09/20 Vuzix reports Q3 EPS (13c), consensus (12c) 08/10/20 Vuzix reports Q2 EPS (13c), consensus (15c) 12/02/20 Ideanomics' Treeletrik appoints Richard Teoh as CFO 12/08/20 GameStop reports Q3 adj. EPS (53c), consensus (85c) 12/08/20 GameStop reports Q3 EPS (29c), consensus (85c) 12/08/20 Notable companies reporting after market close 09/09/20 GameStop reports Q2 adj. EPS ($1.40), consensus ($1.13) 08/11/20 BioNTech reports Q2 EPS (EUR38c), consensus (EUR24c) 07/31/20 Pfizer, BioNTech to supply Japan with 120M doses of BNT162 vaccine candidate 07/20/20 U.K. government inks COVID deals with BioNTech/Pfizer, AstraZeneca
Recommendations
BTIG analyst Mark Massaro…
Show Hide Related Items >> <<
01/18/21 AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer 01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC 01/12/21 AstraZeneca to present new data from lung cancer portfolio at WCLC ADPT Adaptive Biotechnologies 01/11/21 Adaptive in pact with AstraZeneca to investigate use of immunoSEQ T-MAP 12/06/20 Adaptive announces new data demonstrating impact of clonoSEQ Assay 11/13/20 Adaptive Biotechnologies announces preliminary data on T-Detect Assay 08/06/20 Adaptive Biotechnologies receives expanded FDA clearance for clonoSEQ Assay ADPT Adaptive Biotechnologies 12/17/20 BTIG BTIG positive on select healthcare diagnostic/tools names as '2021 Top Picks' 11/12/20 BTIG Adaptive Biotechnologies price target raised to $63 from $60 at BTIG 11/11/20 JPMorgan Adaptive Biotechnologies price target raised to $60 from $50 at JPMorgan 10/07/20 BTIG Adaptive Biotechnologies initiated with a Buy at BTIG 01/15/21 Berenberg AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg 01/15/21 Fly Intel: Top five analyst initiations 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER ADPT Adaptive Biotechnologies 11/10/20 Adaptive Biotechnologies reports Q3 EPS (27c), consensus (28c) 08/10/20 Adaptive Biotechnologies reports Q2 EPS (26c), consensus (28c)
Yesterday
Periodicals
New York Governor Andrew…
New York Governor Andrew Cuomo asked Pfizer Inc Chief Executive Albert Bourla on Monday if the state could buy COVID-19 vaccine doses directly from the U.S. drugmaker, Reuters' Kanishka Singh reports. Pfizer, however, told Reuters that such a proposal would first require approval by the U.S. Department of Health and Human Services. Reference Link
Show Hide Related Items >> <<
01/14/21 Pfizer says FDA approves supplemental NDA for Xalkori 01/14/21 Oragenics issues letter to stockholders on Terra CoV-2 01/13/21 Siga Technologies: Meridian Medical to purchase up to $33M of oral TPOXX 01/12/21 Canada orders 20M more doses of Pfizer, BioNTech Covid vaccine 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 01/12/21 Pfizer, health officials investigating post-vaccine fatality, Bloomberg says 01/11/21 Pfizer says HHS would need to approve direct sales of COVID vaccine, CNBC says 01/04/21 Pfizer, BioNTech offered South Africa discounted vaccines, Bloomberg says 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th
Hot Stocks
AstraZeneca and Daiichi…
AstraZeneca and Daiichi Sankyo said Enhertu has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. The approval by the Food and Drug Administration was based on the positive results from the randomized DESTINY-Gastric01 Phase II trial conducted in Japan and South Korea. Enhertu is approved with Boxed Warnings for interstitial lung disease or pneumonitis and embryo-fetal toxicity. This is the second indication approved for Enhertu in the U.S. following the accelerated approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting based on the DESTINY-Breast01 trial.
Show Hide Related Items >> <<
01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC 01/12/21 AstraZeneca to present new data from lung cancer portfolio at WCLC 01/12/21 AstraZeneca, Recombinetics announce research collaboration on NF1 01/15/21 Berenberg AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg 01/15/21 Fly Intel: Top five analyst initiations 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER 01/17/21 Pakistan approves AstraZeneca COVID vaccine for emergency use, Reuters says 01/15/21 AstraZeneca's COVISHIELD vaccine approved by Nepal, Reuters reports 01/03/21 AstraZeneca/Oxford COVID vaccine authorized by India, WSJ reports 12/30/20 U.S. EUA for AstraZeneca's COVID vaccine likely in April, Reuters reports 12/30/20 Fly Intel: Wall Street's top stories for Wednesday 12/30/20 Fly Intel: Wall Street's top stories at midday 12/30/20 AstraZeneca upgrade, Spotify target change among top calls on Wall Street 12/30/20 Fly Intel: Pre-market Movers 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th 12/28/20 Unusually active option classes on open December 28th 12/14/20 AstraZeneca call volume above normal and directionally bullish
Friday
Recommendations
Berenberg analyst Luisa…
Berenberg analyst Luisa Hector lowered the firm's price target on AstraZeneca to 10,000 GBp from 10,500 GBp and keeps a Buy rating on the shares.
Show Hide Related Items >> <<
01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC 01/12/21 AstraZeneca to present new data from lung cancer portfolio at WCLC 01/12/21 AstraZeneca, Recombinetics announce research collaboration on NF1 01/15/21 Fly Intel: Top five analyst initiations 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 12/30/20 Fly Intel: Top five analyst calls 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER 01/15/21 AstraZeneca's COVISHIELD vaccine approved by Nepal, Reuters reports 01/03/21 AstraZeneca/Oxford COVID vaccine authorized by India, WSJ reports 12/30/20 U.S. EUA for AstraZeneca's COVID vaccine likely in April, Reuters reports 12/29/20 Indonesia finalizing vaccine deals with Pfizer, AstraZeneca, Reuters reports 12/30/20 Fly Intel: Wall Street's top stories for Wednesday 12/30/20 Fly Intel: Wall Street's top stories at midday 12/30/20 AstraZeneca upgrade, Spotify target change among top calls on Wall Street 12/30/20 Fly Intel: Pre-market Movers 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th 12/28/20 Unusually active option classes on open December 28th 12/14/20 AstraZeneca call volume above normal and directionally bullish
Initiation
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AstraZeneca (AZN) initiated with a Buy at Deutsche Bank. 2. Allakos (ALLK) initiated with a Buy at BofA. 3. Skillz (SKLZ) initiated with an Equal Weight at Wells Fargo. 4. Anaplan initiated with an Outperform rating at William Blair. 5. Allegheny Technologies (ATI) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Show Hide Related Items >> <<
01/05/21 Anaplan names Bill Schuh as Chief Revenue Officer 11/12/20 Anaplan CEO sells 45K shares of common stock 09/23/20 Anaplan CEO: We're working with companies to provide business agility 09/22/20 Google Cloud, Anaplan team to offer Anaplan's enterprise platform on Google 01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC 01/12/21 AstraZeneca to present new data from lung cancer portfolio at WCLC 01/12/21 AstraZeneca, Recombinetics announce research collaboration on NF1 ATI Allegheny Technologies 12/02/20 Allegheny Technologies exits stainless sheet biz ,focus on aerospace, defense 09/18/20 D.E. Shaw reports 5.0% passive stake in Allegheny Technologies 09/04/20 Etsy, Teradyne, Catalent to join S&P 500 08/04/20 Allegheny Technologies sees uncertain economic conditions to persist in FY20 10/26/20 Allakos reports results from prospective prevalence study 10/26/20 Allakos announces results from Phase 1 study of lirentelimab 10/21/20 Allakos study shows clinically meaningful,statistically significant benefits 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 12/30/20 Fly Intel: Top five analyst calls 12/30/20 AlphaValue AlphaValue upgrades AstraZeneca, sees sentiment 'finally' improving 01/15/21 BofA Allakos initiated with a Buy at BofA 12/21/20 SVB Leerink SVB Leerink bullish on Allakos, initiates with an Outperform 12/21/20 SVB Leerink Allakos initiated with an Outperform at SVB Leerink 03/25/20 Jefferies Allakos starts two pivotals on time despite skepticism, says Jefferies 01/15/21 Wells Fargo Skillz initiated with an Equal Weight at Wells Fargo 01/12/21 Wedbush Skillz initiated with an Outperform at Wedbush 01/12/21 Fly Intel: Top five analyst initiations 01/12/21 Stifel Skillz initiated with a Buy at Stifel 01/15/21 William Blair Blair starts Anaplan at Outperform, calls attractive acquisition target 01/11/21 Piper Sandler Anaplan upgraded to Overweight from Neutral at Piper Sandler 01/11/21 Jefferies Anaplan upgraded to Buy from Hold at Jefferies 01/05/21 Wells Fargo Anaplan upgraded to Overweight from Equal Weight at Wells Fargo ATI Allegheny Technologies 01/15/21 Seaport Global Allegheny Technologies initiated with a Buy at Seaport Global 12/07/20 KeyBanc Allegheny Technologies price target raised to $25 from $15 at KeyBanc 12/04/20 Fly Intel: Top five analyst upgrades 12/04/20 Benchmark Benchmark upgrades Allegheny Technologies to Buy after commodity stainless exit 11/25/20 Anaplan sees FY22 revenue around $550M, consensus $552.1M 11/24/20 Anaplan raises FY21 revenue view to $444M-$445M, consensus $438.63M 11/24/20 Anaplan sees Q4 revenue $118.5M-$119.5 , consensus $118.42M 11/24/20 Anaplan reports Q3 EPS (5c), consensus (10c) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER ATI Allegheny Technologies 10/29/20 Allegheny Technologies reports Q3 adj. EPS (38c), consensus (60c) 08/04/20 Allegheny Technologies reports Q2 adj. EPS (2c), consensus (12c) 11/09/20 Allakos reports Q3 EPS (86c), consensus (82c) 10/27/20 Allakos sees Q3 net loss of ($50M) to ($40M) vs. ($21.7M) last year 08/10/20 Allakos reports Q2 EPS (80c), consensus (61c)
Hot Stocks
Aveo Oncology (AVEO)…
Aveo Oncology (AVEO) announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib, Aveo's vascular endothelial growth factor receptor tyrosine kinase inhibitor, or TKI, drug candidate, in combination with Imfinzi, AstraZeneca's (AZN) human monoclonal antibody directed against programmed death-ligand 1, or PD-L1, in patients with advanced or metastatic hepatocellular carcinoma, or HCC. The results are being presented in a poster session at the 2021 American Society of Clinical Oncology Gastrointestinal, or ASCO GI, Cancers Symposium being held virtually. A total of seven patients with advanced or metastatic HCC were enrolled in the Phase 1b portion of the study, which was designed to determine the recommended Phase 2 dose and assess preliminary safety and efficacy of the tivozanib/durvalumab combination. Patients received 1.0 mg of tivozanib for 21 days followed by 7 days off therapy combined with 1500 mg of durvalumab every 28 days. The combination was well tolerated, with no dose-limiting toxicities. The combination demonstrated a 29% partial response rate and 71% disease control rate. Completion of enrollment in the ongoing Phase 2 portion of the study, which is expected to enroll up to an additional 30 subjects, is anticipated later this year.
Show Hide Related Items >> <<
01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC 01/12/21 AstraZeneca to present new data from lung cancer portfolio at WCLC 01/12/21 AstraZeneca, Recombinetics announce research collaboration on NF1 01/11/21 Adaptive in pact with AstraZeneca to investigate use of immunoSEQ T-MAP AVEO Aveo Pharmaceuticals 11/09/20 Aveo Pharmaceuticals sees funding for operations into 2022 11/05/20 Aveo Pharmaceuticals announces TiNivo study results published 09/15/20 Aveo says Phase 3 TIVO-3 results published in European Urology 09/08/20 AVEO Oncology regains full global rights to ficlatuzumab AVEO Aveo Pharmaceuticals 11/09/20 Fly Intel: Top five analyst initiations 11/09/20 Stifel Aveo Pharmaceuticals initiated with a Buy at Stifel 08/13/20 SVB Leerink SVB Leerink bullish on Aveo Pharmaceuticals, initiates with an Outperform 08/13/20 SVB Leerink Aveo Pharmaceuticals initiated with an Outperform at SVB Leerink 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 12/30/20 Fly Intel: Top five analyst calls 12/30/20 AlphaValue AlphaValue upgrades AstraZeneca, sees sentiment 'finally' improving 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER AVEO Aveo Pharmaceuticals 11/09/20 Aveo Pharmaceuticals reports Q3 EPS (33c), consensus (24c) 08/10/20 Aveo sees cash, cash equivalents as of June 30 $79.5M 08/10/20 Aveo reports Q2 EPS (42c), consensus (51c)
Periodicals
Nepal granted approval…
Nepal granted approval for AstraZeneca's COVISHIELD vaccine against the coronavirus, Reuters' Gopal Sharma and Alasdair Pal report, citing the government. The approval follows a meeting with neighboring India, a major manufacturer of the shot, the report noted. "Conditional permission has been granted for emergency use authorization of COVISHIELD vaccine against COVID-19 in Nepal," the Department of Drug Administration said. Reference Link
Show Hide Related Items >> <<
01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC 01/12/21 AstraZeneca to present new data from lung cancer portfolio at WCLC 01/12/21 AstraZeneca, Recombinetics announce research collaboration on NF1 01/11/21 Adaptive in pact with AstraZeneca to investigate use of immunoSEQ T-MAP 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank 01/08/21 Raymond James Alexion downgraded to Market Perform from Outperform at Raymond James 12/30/20 Fly Intel: Top five analyst calls 12/30/20 AlphaValue AlphaValue upgrades AstraZeneca, sees sentiment 'finally' improving 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER 01/03/21 AstraZeneca/Oxford COVID vaccine authorized by India, WSJ reports 12/30/20 U.S. EUA for AstraZeneca's COVID vaccine likely in April, Reuters reports 12/29/20 Indonesia finalizing vaccine deals with Pfizer, AstraZeneca, Reuters reports 12/28/20 AstraZeneca says shot to be effective against COVID-19 variant, AP reports 12/30/20 Fly Intel: Wall Street's top stories for Wednesday 12/30/20 Fly Intel: Wall Street's top stories at midday 12/30/20 AstraZeneca upgrade, Spotify target change among top calls on Wall Street 12/30/20 Fly Intel: Pre-market Movers 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th 12/28/20 Unusually active option classes on open December 28th 12/14/20 AstraZeneca call volume above normal and directionally bullish